Development of therapy for endometriosis.

子宫内膜异位症是一种常见的妇科疾病，与盆腔疼痛和不孕有关。目前的治疗方法包括口服避孕药联合NSAID或手术切除病变，所有这些都提供了暂时但不完全的治愈。由于大多数子宫内膜异位症发生在面向腹膜的器官表面，我们减去了噬菌体展示库与雌性小鼠腹膜组织和选择的噬菌体克隆结合到人子宫内膜上皮细胞。我们确定了一个由细胞内化的靶向肽，命名为z13。蛋白质组学分析显示z13受体为CNGB3。然后，我们将z13与凋亡诱导肽和内体逃逸肽连接。当这些肽共同管理到狒狒的腹膜子宫内膜异位症，病变细胞选择性地进行细胞凋亡，对邻近器官没有影响。这项研究报告了一种潜在的治疗能够消除子宫内膜异位症从人类腹膜。

Endometriosis is a common gynecological disease associated with pelvic pain and infertility. Current treatments include oral contraceptives combined with NSAIDs or surgery to remove lesions, all of which provide a temporary but not complete cure. As most endometriosis occurs on organ surfaces facing the peritoneum, we subtracted a phage display library with female mouse peritoneum tissue and selected phage clones by binding to human endometrial epithelial cells. We identify an endometriosis-targeting peptide internalized by cells, designated z13. Proteomics analysis revealed the z13 receptor as the CNGB3. We then linked z13 with an apoptosis inducing peptide and with an endosome-escaping peptide. When these peptides were coadministered into the peritoneum of baboons with endometriosis, cells in lesions selectively underwent apoptosis with no effect on neighboring organs. This study reports a potential therapeutic capable of eliminating endometriosis from the human peritoneum.